Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.
Charles L. Raison, Rakesh Jain, Andrew Penn, Steven P Cole, Saundra Jain
Frontiers in Psychiatry 2022 DOI: 10.3389/fpsyt.2022.831092 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 2,510 |
| Population | Adults with at least one lifetime psychedelic experience |
| Topics | Anxiety Ayahuasca Depression Psilocybin |
| Keywords | Harms Patterns of use Psychedelics Well-being |
| Citations | 75 |
| Key findings | Psychedelic use was associated with significant improvements in depressive and anxious symptoms and increased emotional well-being, with greater use linked to larger benefits up to a ceiling, but 13% of participants reported at least one harm from use. |
Abstract
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A cross-sectional, online survey was completed by 2,510 adults reporting at least one lifetime psychedelic experience. Participants retrospectively completed a battery of instruments assessing depression, anxiety, and emotional well-being prior to and following psychedelic exposure. Participants also reported preferred psychedelic agent, number of uses, and harms attributed to psychedelic use. Psychedelic use was associated with significant improvements in depressive and anxious symptoms and with increased emotional well-being. These improvements increased in magnitude with increasing psychedelic exposure, with a ceiling effect. However, improvements were noted following a single lifetime use. Strong evidence for benefit of one preferred psychedelic agent over another was not observed, but enduring increases in factors related to mystical-experience and prosocial perspective taking associated with enhanced mental health. Thirteen percent of the survey sample (n = 330) endorsed at least one harm from psychedelic use, and these participants reported less mental health benefit. Results from the current study add to a growing database indicating that psychedelic use-even outside the context of clinical trials-may provide a wide range of mental health benefits, while also posing some risk for harm in a minority of individuals.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
Psychedelic use was associated with significant improvements in depressive and anxious symptoms and well-being, with a ceiling effect, though 13% reported at least one harm from use.
Synthesized
-
Psychedelic use was associated with significant improvements in depressive and anxious symptoms and well-being, with benefits increasing with exposure up to a ceiling, though 13% reported at least one harm.
Synthesized
Comparable studies
Other cross-sectional and survey studies on ayahuasca for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychological and neuropsychological assessment of regular hoasca users. Regular hoasca users from a U.S. branch of União do Vegetal and matched non-user controls | 2016 | Cross-sectional study | n = 57 |
| Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers People reporting depression or anxiety diagnoses at the time of consuming ayahuasca in... | 2021 | Cross-sectional survey | n = 2,011 |
Citations in the library
Cited by 70
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment Neuropharmacology January 13, 2023
- The economics of psychedelic-assisted therapies: A research agenda Frontiers in Psychiatry December 5, 2022
- Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom Journal of Affective Disorders January 26, 2024
- Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology April 1, 2024
- A framework for assessment of adverse events occurring in psychedelic-assisted therapies Journal of Psychopharmacology July 31, 2024
and 65 more in the library
Cites 34
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 29 more in the library